Skeletal muscle glucose transport and mitochondrial function in type 1 diabetes

Vrije Universiteit Amsterdam0 个研究点目标入组 32 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, participants with T1DM must meet all of the following criteria:
•Individuals with T1DM with a diagnosed disease duration of 1 – 45 years
•Male or female
•Aged between 18-65 years
•In order to be eligible to participate in this study, healthy control participants must meet all of the following criteria:
•No chronic health conditions and between the ages of 18-65

•History of asthma, stroke, chronic obstructive pulmonary disease, congestive heart failure, heart surgery, or congenital heart diseases
•Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 receptor agonists
•Are current smokers or have been a regular smoker within the last 12 months
•Insulin pump therapy
•Symptomatic autonomic or distal neuropathy
•BMI >30 due to adiposity, since this is known to cause difficulties in obtaining muscle biopsies.
•Recent acute myocardial infarction (<6 months)
•Uncontrolled arrhythmia/severe conduction disorder (atrial fibrillation or second/third degree AV block) causing hemodynamic compromise
•Implantable pacemaker or other cardiac device with complete ventricular pacing
•Uncontrolled heart failure with hemodynamic compromise
•Uncontrolled hypertension (Systolic Blood Pressure >150 mmHg and Diastolic Blood Pressure > 100 mmHg on repeated measurements)
•Active infection, anaemia, severe renal dysfunction (estimated Glomerular filtration rate <30 ml/min/1,73m2) likely to significantly impact on exercise performance
•Chronic illness (including orthopaedic, endocrinological, haematological, malignant, gastrointestinal, neurological, muscle or inflammatory disorders) likely to significantly impact on exercise performance
•> 6 alcohol units per day or >14 alcohol units per week
•Use of anticoagulants or anti platelet therapy

发起方